Background Proton pump inhibitors (PPI s) have a well‐established safety profile. However,
concerns have been raised about a potential relationship between PPI‐induced …

Background: Long-term use of proton pump inhibitors (PPI) has been reported to worsen
oxyntic mucosa gastritis and the resulting gland atrophy has been considered a potential …

Neuroendocrine tumors (NETs) throughout the body are the focus of much current interest.
Most occur in the gastrointestinal tract and have shown a major increase in incidence over …

Background Proton pump inhibitors (PPIs) are the most effective drugs to reduce gastric acid
secretion. PPIs are one of the most commonly prescribed classes of medications worldwide …

Materials and Methods: A PubMed search was conducted to identify studies using the
keywords proton pump inhibitors or PPI and gastric atrophy or atrophic gastritis; the …

BACKGROUND: Proton pump inhibitors (PPIs) are the most effective agents available for
reducing acid secretion. They are used for medical treatment of various acid-related …

Objective Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy,
particularly in Helicobacter pylori (HP)-infected subjects. We determined the association …

Recently, two epidemiological studies showed that long-term treatment with proton pump
inhibitors (PPIs) increased the risk of gastric cancer. It is well known that hypergastrinemia …

Proton pump inhibitors (PPIs) are recommended as a first-line treatment for
gastroesophageal reflux disease (GERD) and other acid related disorders. In recent years …

Gastric cancer remains one of the leading cancers in the world with a high mortality,
particularly in East Asia. Helicobacter pylori infection accounts for the majority of the …